中国实用内科杂志2014，Vol.34Issue(6)：558-560,3.DOI:10.7504/nk2014050103
妊娠期乙型肝炎病毒感染者抗病毒治疗进展及争议
Antiretroviral therapy progress and controversy of HBV-infected pregnancy
裴彬 1缪晓辉2
作者信息
- 1. 上海国际医学中心医院感染科,上海201318
- 2. 第二军医大学长征医院感染科,上海200003
- 折叠
摘要
Abstract
All decisions about initiating,continuing,or stopping therapy of the hepatitis B virus (HBV) during pregnancy must include an analysis of the risks and benefits for mother and fetus.The trimester of the pregnancy and the stage of the mother's liver disease are important factors.Treatment in the third trimester may be initiated to aid in preventing perinatal transmission,which appears to be most pronounced in mothers with high viral loads.Currently,lamivudine,telbivudine and tenofovir appear to be the therapeutic options with the most reasonable safety data in pregnancy.关键词
乙型肝炎病毒/妊娠/母婴传播/拉米夫定/替诺福韦/替比夫定Key words
hepatitis B / pregnancy/ mother-to-child-transmission/ Lamivudine/ Tenofovir/ Telbivudine分类
医药卫生引用本文复制引用
裴彬,缪晓辉..妊娠期乙型肝炎病毒感染者抗病毒治疗进展及争议[J].中国实用内科杂志,2014,34(6):558-560,3.
